Quantitative analysis of the IgG and IgG subclass immune responses to chromosomal Pseudomonas aeruginosa beta-lactamase in serum from patients with cystic fibrosis by western blotting and laser scanning densitometry

Thorax. 1996 Jul;51(7):733-8. doi: 10.1136/thx.51.7.733.

Abstract

Background: Antibodies against chromosomal beta-lactamase of Pseudomonas aeruginosa (a beta ab) are markers of the development of resistance of P aeruginosa to beta-lactam antibiotics in patients with cystic fibrosis and chronic lung infection. The role of these antibodies in patients with chronic lung infection with P aeruginosa was further investigated by correlating the a beta ab IgG subclasses with pulmonary function in patients with cystic fibrosis.

Methods: Immunoglobulin G (IgG) and IgG subclass a beta ab were investigated by western blotting and quantified by laser scanning densitometry. A longitudinal study on 43 consecutive patients with cystic fibrosis who developed chronic lung infection with P aeruginosa was performed.

Results: IgG subclass a beta ab appeared in all patients with chronic infection with P aeruginosa. Eleven years after the onset of infection all the patients had IgG1, 79% had IgG4, 56% IgG2, and only 16% of the patients had IgG3 a beta ab. The IgG1 and IgG4 a beta ab appeared first, and more than 50% of the patients were IgG1 and IgG4 a beta ab positive within 2-3 years of the onset of infection, but IgG2 positivity only appeared after seven years and IgG3 remained absent from most of the patients. The median a beta ab levels increased during chronic infection: 100-fold for IgG1, 22-fold for IgG2, and 45-fold for IgG4. A 16-fold increase in the IgG3 a beta ab levels was detected in the six patients who developed IgG3 a beta ab. In the first four years of the chronic infection the a beta ab titres were higher in patients with good lung function than in those with poor lung function.

Conclusions: The association of a weak IgG3 and a strong IgG4 a beta ab response suggests that the contribution of a beta ab antibodies to lung diseases mediated by immune complexes might be less important than other antipseudomonal antibodies. A beneficial neutralising effect of the a beta ab antibodies on the antibiotic destroying enzymes may be an additional factor.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Anti-Bacterial Agents
  • Blotting, Western
  • Child
  • Child, Preschool
  • Chronic Disease
  • Cystic Fibrosis / complications
  • Cystic Fibrosis / immunology
  • Cystic Fibrosis / microbiology*
  • Densitometry
  • Drug Resistance, Microbial
  • Humans
  • Immunoglobulin G / blood*
  • Infant
  • Longitudinal Studies
  • Middle Aged
  • Pseudomonas Infections / complications
  • Pseudomonas Infections / enzymology*
  • Pseudomonas Infections / immunology
  • Pseudomonas aeruginosa*
  • Respiratory Function Tests
  • beta-Lactamases / immunology*
  • beta-Lactams

Substances

  • Anti-Bacterial Agents
  • Immunoglobulin G
  • beta-Lactams
  • beta-Lactamases